Objective: The optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established. Methods: The records of elderly (!70 years of age) patients with LD-SCLC who had been treated with etoposide and cisplatin chemotherapy with early concurrent twice-daily thoracic radiotherapy (TRT) were reviewed retrospectively. Results: Of the 25 elderly patients with LD-SCLC identified, 12 (48%) individuals received etoposide-cisplatin chemotherapy with early concurrent twice-daily TRT. The main toxicities of this treatment regimen were hematologic, with neutropenia of Grade 4 being observed in all patients and febrile neutropenia of Grade 3 in eight patients during the first cycle of chemoradiotherapy. The toxicity of TRT was acceptable, with all patients completing the planned radiotherapy within a median of 29 days (range, 19-33). No treatment-related deaths were observed. The median progression-free survival and overall survival times were 14.2 months (95% confidence interval, 4.3-18.2) and 24.1 months (95% confidence interval, 11.3-27.2), respectively. Conclusions: Etoposide -cisplatin chemotherapy with early concurrent twice-daily TRT was highly myelotoxic in elderly patients with LD-SCLC, although no treatment-related deaths were observed in our cohort. Prospective studies are required to establish the optimal schedule and dose of chemotherapy and TRT in such patients.
INTRODUCTION
Small cell lung cancer (SCLC) accounts for 10 -15% of all lung cancer cases, with individuals aged 70 years or older constituting up to 25 -40% of the SCLC patients (1, 2) . Limited-disease (LD) SCLC is a disease that is confined to one hemithorax and its regional lymph nodes and which can be encompassed by a single radiation therapy port. About 30 -40% of all SCLC patients present with LD-SCLC (1, 2) . The proportion of elderly SCLC patients continues to increase with the growing geriatric population (1, 3) .
The combination of radiotherapy and chemotherapy, specifically etoposide and cisplatin chemotherapy with early concurrent twice-daily thoracic radiotherapy (TRT), is now regarded as the standard treatment for LD-SCLC (4). However, many clinical trials of potential new treatments for LD-SCLC have excluded elderly patients for various reasons, such as the presence of concomitant chronic illness, a decline in organ function that may interfere with drug clearance and possible decreased bone marrow tolerance to myelosuppressive agents (5) . The optimal management of elderly patients with LD-SCLC has therefore not been defined to date.
We have now performed a retrospective analysis to evaluate patient characteristics as well as treatment delivery, toxicity and antitumor efficacy for elderly individuals (70 years or older) with LD-SCLC who were treated with etoposide and cisplatin chemotherapy and early concurrent twice-daily TRT.
PATIENTS AND METHODS
We retrospectively evaluated the records of elderly (!70 years) patients with LD-SCLC who were treated at Kinki University School of Medicine from January 2003 to December 2008. All patients had a pathological diagnosis of SCLC. LD-SCLC was defined as cancer that is confined to one hemithorax including contralateral mediastinal and hilar lymph nodes as well as ipsilateral or bilateral supraclavicular lymph nodes, but excluding malignant pleural effusion. Response evaluation was assessed after completion of treatment on the basis of the Response Evaluation Criteria in Solid Tumors (RECIST). Laboratory testing and toxicities were graded weekly during the whole treatment according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 3). Progression-free survival time was measured from the date of initiation of treatment to the date of disease progression. Overall survival time was measured from the date of initiation of treatment to death or to the time that the patient was last known to be alive. After completion of all treatment, patients were followed up at 1-to 2-month intervals until the time of progression or death. Median progression-free survival time and overall survival time were estimated by the Kaplan-Meier method.
RESULTS

PATIENT CHARACTERISTICS
Of the 170 SCLC patients treated between 2003 and 2008, 48 individuals were diagnosed with LD-SCLC and 25 of these individuals were 70 years of age or older. Among these 25 patients, 12 (48%) elderly patients with LD-SCLC received etoposide and cisplatin chemotherapy with early concurrent twice-daily TRT. The characteristics of these 12 patients are shown in Table 1 . They included eight men and four women as well as seven individuals aged between 70 and 74 years and five aged 75 years or older. All the patients were in good general condition, although they had some complications. The remaining 13 patients' characteristics are shown in Table 2 . Two of the 13 elderly patients with LD-SCLC were treated with chemotherapy and sequential TRT, and 1 patient was treated with etoposide -carboplatin and concurrent TRT. Chemotherapy alone was administered in 4 of the 13 patients. Two patients were subjected to surgery followed by chemotherapy. Four patients did not receive intensive therapy.
TREATMENT DELIVERY
The treatment plan consisted of an initial cycle of concurrent chemoradiotherapy followed by three cycles of consolidation chemotherapy (Table 3 ). All patients received the same chemotherapy regimen of cisplatin at 40 -80 mg/m 2 on day 1 combined with etoposide at 80 -100 mg/m 2 on days 1 -3. Twice-daily TRT was performed with X-rays at 6 -10 MV and with an interval of at least 6 h and a total dose of 45 Gy (1.5 Gy bid) over 3 weeks. TRT was initiated on day 1 of the first cycle of chemotherapy. All patients completed the TRT protocol, with the days of irradiation ranging from 19 to 33 (median of 29). Reasons for a delay in TRT included febrile neutropenia of Grade 3 in eight patients and leukopenia of Grade 4 in three patients. All patients proceeded to consolidation chemotherapy. However, five patients (42%) did not complete the planned three cycles of consolidation chemotherapy because of the development of pneumonitis of Grade 3 in one patient, a decline in renal function in one patient, suspected invasive aspergillosis in one patient and refusal by two patients. A dose reduction was necessary in seven patients because of the development of febrile neutropenia of Grade 3 in three patients, leukopenia of Grade 4 in two patients and nausea -vomiting of Grade 3 in two patients. The actual dose intensities of cisplatin and etoposide were 13.7 mg/m 2 /week (68.7% of the planned dose intensity) and 52.4 mg/m 2 /week (69.9% of the planned dose intensity), respectively.
TOXICITIES
Reported toxicities during the concurrent chemoradiotherapy are listed in Table 4 . Leukopenia and neutropenia of Grade 3 or 4 were observed in all patients (100%), and eight patients (67%) had febrile neutropenia of Grade 3. Thrombocytopenia of Grade 3 or 4 was apparent in three patients (25%), with one patient requiring platelet transfusion. Reported toxicities during the consolidation chemotherapy are listed in Table 5 . Leukopenia and neutropenia of Grade 3 or 4 were observed in 8 (67%) and 11 (92%) patients, respectively, and 4 patients (33%) developed febrile neutropenia of Grade 3. Anemia and thrombocytopenia of Grade 3 or 4 were each observed in four patients (33%). The major non-hematologic toxicity observed during the entire treatment period was nausea -vomiting. None of the patients developed esophagitis of Grade 3 or 4, but one patient manifested radiation pneumonitis of Grade 3 during consolidation chemotherapy. There were no treatmentrelated deaths.
RESPONSE AND SURVIVAL
All 12 patients were evaluated for progression-free survival and overall survival. With a median follow-up time of 23.1 months (ranged, 7.2 -45.0 months), six patients were still alive. An objective tumor response was observed in all patients: a complete response (CR) in five patients and a partial response in seven patients (Table 3) . Prophylactic cranial irradiation was not routinely administered and delivered to three patients who achieved CR after completion of the planned treatment. The median progression-free survival time was 14.2 months, and the median overall survival time was 24.1 months.
PATTERN OF RELAPSE
Seven of the 12 patients relapsed, 3 with local regional failure inside the radiation field and 4 with distant failure. Among the latter four patients, three individuals manifested metastases in the brain as the sole site and the remaining individual had both local and distant failure including the liver.
DISCUSSION
Two meta-analyses have shown that the combined modality of chemotherapy and TRT improves the survival of individuals with LD-SCLC in comparison with chemotherapy alone (6,7). The schedule, dose and fractionation of TRT have been extensively investigated in patients with LD-SCLC in several randomized controlled trials (8, 9) . On the basis of two pivotal Phase III trials (10,11), etoposide and cisplatin 
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Optimal management of elderly patients with LD-SCLC chemotherapy with early concurrent twice-daily TRT is currently considered the standard treatment for patients with LD-SCLC. An age-specific subset analysis of one of these Phase III trials (11) , in which patients received etoposidecisplatin with early concurrent TRT, showed that the survival outcomes for individuals aged 70 years or older were similar to those of their younger counterparts, although the elderly patients experienced greater toxicity, in particular hematologic toxicity (12) . However, given that the patients in this subgroup analysis were assigned either once-or twice-daily TRT, the significance of early concurrent twice-daily TRT in the management of elderly patients with LD-SCLC has remained undefined. No specific Phase III trial of elderly patients with LD-SCLC has been reported. We therefore retrospectively analyzed the feasibility and antitumor efficacy of etoposide -cisplatin chemotherapy with early concurrent twice-daily TRT for treatment of LD-SCLC in patients aged 70 years or older. The median overall survival time of 24.1 months in our cohort is similar to that described for non-elderly patients with LD-SCLC in previous studies (10, 11) . This favorable survival outcome may be attributable to the strict selection of elderly patients in good general condition; all 12 patients in the present study had normal organ function, an Eastern Cooperative Oncology Group performance status of 0 or 1 and no severe co-morbidity. Given that the elderly are more likely to have reduced organ function as well as concomitant morbidities or medications, the general condition of elderly SCLC patients is worse than that of younger patients (1). Among LD-SCLC patients, increasing age was found to be significantly associated with a lower likelihood of receiving combined chemoradiotherapy (7) . Indeed, in the present study, only 12 (48%) of the 25 identified elderly patients with LD-SCLC were treated with etoposide -cisplatin and early concurrent twice-daily TRT. Despite the strict selection of patients, highly treatment-related toxicity was observed in our cohort. The major adverse events were hematologic toxicities, with neutropenia of Grade 4 being apparent in all patients (100%) and febrile neutropenia of Grade 3 in eight patients (67%) during the first cycle of concurrent chemoradiotherapy. The previous analysis of the outcome of elderly patients in the Phase III study in which individuals received etoposidecisplatin chemotherapy with early concurrent once-or twicedaily TRT found statistically significant differences not only in the incidence of hematologic toxicity (Grade 4 or 5: 61% in younger patients vs. 84% in patients aged 70 years or older, P , 0.01) but also in that of treatment-related deaths (1% vs. 10%, respectively, P ¼ 0.01) (12) . Although no treatment-related deaths were observed in the present study, severe hematologic toxicity was consistent with that in this foregoing analysis (12) . In addition, maintenance of the optimal dose intensity of chemotherapy was difficult in our cohort because of frequent dose reductions or treatment delays due to hematologic or infection-related toxicities. Indeed, the actual dose intensity was ,70% of the planned dose intensity for both etoposide and cisplatin in the present study, a value much smaller than that for non-elderly patients in a previous Phase III study (.90% for both agents) (10) . On the other hand, the toxicity of radiotherapy was acceptable in our study, with all patients completing TRT within a median of 29 days (range, 19 -33). None of our patients developed radiation esophagitis of Grade 3 or higher. With regard to pulmonary complications, one patient developed radiation pneumonitis of Grade 3. A recent meta-analysis of randomized trials in which patients with LD-SCLC were treated with chemoradiotherapy reported that the time between the first day of chemotherapy and the last day of radiotherapy was an important prognostic factor for LD-SCLC, with the survival advantage being more pronounced if the TRT was completed in ,30 days (13) . In the present study, a shorter time to completion of TRT may also be associated with our favorable survival outcome. However, elderly patients with LD-SCLC must be carefully selected and monitored during treatment because of the increased potential for the development of treatment-related morbidity and mortality.
The optimal therapeutic strategy for elderly patients with LD-SCLC remains a matter of debate. Despite the highly treatment-related toxicity, patients in our cohort derived a survival benefit with no treatment-related deaths, suggesting that the full-dose chemoradiotherapy may represent a valid option for 'fit' elderly patients with adequate organ function. Since the general condition of elderly patients varies widely from patients to patients, prospective evaluation and definition of 'fit' elderly patients who are candidates for fulldose chemoradiotherapy are important. Research is also needed to develop modified chemoradiotherapy regimens that are less toxic for the elderly. A modified chemotherapy schedule designed to reduce toxicity for elderly patients with LD-SCLC was evaluated in a Phase II trial, with two cycles of a chemotherapy regimen (oral etoposide and carboplatin) combined with early concurrent twice-daily TRT being found to have acceptable toxicity and to produce promising results, with a 5-year survival rate of 13% (14) . A recent Phase III trial specifically designed for elderly or poor-risk patients with extensive-disease SCLC found that split doses of cisplatin plus etoposide (cisplatin at 25 mg/m 2 and etoposide at 80 mg/m 2 on days 1 -3) could be safely administered and were effective (15) . Such split-dose chemotherapy might also be suitable for the treatment of patients with LD-SCLC. We are currently conducting a clinical trial to evaluate the feasibility of etoposide at 80 mg/m 2 and cisplatin at 25 mg/ m 2 on days 1 -3 with early concurrent twice-daily TRT for elderly patients with LD-SCLC.
The overall findings of the present study suggest that administration of full-dose chemotherapy and early concurrent twice-daily TRT is highly myelotoxic for elderly patients with LD-SCLC. Development and assessment of modified treatment regimens with reduced toxicity are thus warranted for such patients.
